Cargando…

Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in

BACKGROUND: Multiple sclerosis (MS) is a complex chronic inflammatory and degenerative disorder of the central nervous system. Accelerated brain volume loss, or also termed atrophy, is currently emerging as a popular imaging marker of neurodegeneration in affected patients, but, unfortunately, can o...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Schependom, Jeroen, Guldolf, Kaat, D’hooghe, Marie Béatrice, Nagels, Guy, D’haeseleer, Miguel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900860/
https://www.ncbi.nlm.nih.gov/pubmed/31827784
http://dx.doi.org/10.1186/s40035-019-0178-4
_version_ 1783477411750346752
author Van Schependom, Jeroen
Guldolf, Kaat
D’hooghe, Marie Béatrice
Nagels, Guy
D’haeseleer, Miguel
author_facet Van Schependom, Jeroen
Guldolf, Kaat
D’hooghe, Marie Béatrice
Nagels, Guy
D’haeseleer, Miguel
author_sort Van Schependom, Jeroen
collection PubMed
description BACKGROUND: Multiple sclerosis (MS) is a complex chronic inflammatory and degenerative disorder of the central nervous system. Accelerated brain volume loss, or also termed atrophy, is currently emerging as a popular imaging marker of neurodegeneration in affected patients, but, unfortunately, can only be reliably interpreted at the time when irreversible tissue damage likely has already occurred. Timing of treatment decisions based on brain atrophy may therefore be viewed as suboptimal. MAIN BODY: This Narrative Review focuses on alternative techniques with the potential of detecting neurodegenerative events in the brain of subjects with MS prior to the atrophic stage. First, metabolic and molecular imaging provide the opportunity to identify early subcellular changes associated with energy dysfunction, which is an assumed core mechanism of axonal degeneration in MS. Second, cerebral hypoperfusion has been observed throughout the entire clinical spectrum of the disorder but it remains an open question whether this serves as an alternative marker of reduced metabolic activity, or exists as an independent contributing process, mediated by endothelin-1 hyperexpression. Third, both metabolic and perfusion alterations may lead to repercussions at the level of network performance and structural connectivity, respectively assessable by functional and diffusion tensor imaging. Fourth and finally, elevated body fluid levels of neurofilaments are gaining interest as a biochemical mirror of axonal damage in a wide range of neurological conditions, with early rises in patients with MS appearing to be predictive of future brain atrophy. CONCLUSIONS: Recent findings from the fields of advanced neuroradiology and neurochemistry provide the promising prospect of demonstrating degenerative brain pathology in patients with MS before atrophy has installed. Although the overall level of evidence on the presented topic is still preliminary, this Review may pave the way for further longitudinal and multimodal studies exploring the relationships between the abovementioned measures, possibly leading to novel insights in early disease mechanisms and therapeutic intervention strategies.
format Online
Article
Text
id pubmed-6900860
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69008602019-12-11 Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in Van Schependom, Jeroen Guldolf, Kaat D’hooghe, Marie Béatrice Nagels, Guy D’haeseleer, Miguel Transl Neurodegener Review BACKGROUND: Multiple sclerosis (MS) is a complex chronic inflammatory and degenerative disorder of the central nervous system. Accelerated brain volume loss, or also termed atrophy, is currently emerging as a popular imaging marker of neurodegeneration in affected patients, but, unfortunately, can only be reliably interpreted at the time when irreversible tissue damage likely has already occurred. Timing of treatment decisions based on brain atrophy may therefore be viewed as suboptimal. MAIN BODY: This Narrative Review focuses on alternative techniques with the potential of detecting neurodegenerative events in the brain of subjects with MS prior to the atrophic stage. First, metabolic and molecular imaging provide the opportunity to identify early subcellular changes associated with energy dysfunction, which is an assumed core mechanism of axonal degeneration in MS. Second, cerebral hypoperfusion has been observed throughout the entire clinical spectrum of the disorder but it remains an open question whether this serves as an alternative marker of reduced metabolic activity, or exists as an independent contributing process, mediated by endothelin-1 hyperexpression. Third, both metabolic and perfusion alterations may lead to repercussions at the level of network performance and structural connectivity, respectively assessable by functional and diffusion tensor imaging. Fourth and finally, elevated body fluid levels of neurofilaments are gaining interest as a biochemical mirror of axonal damage in a wide range of neurological conditions, with early rises in patients with MS appearing to be predictive of future brain atrophy. CONCLUSIONS: Recent findings from the fields of advanced neuroradiology and neurochemistry provide the promising prospect of demonstrating degenerative brain pathology in patients with MS before atrophy has installed. Although the overall level of evidence on the presented topic is still preliminary, this Review may pave the way for further longitudinal and multimodal studies exploring the relationships between the abovementioned measures, possibly leading to novel insights in early disease mechanisms and therapeutic intervention strategies. BioMed Central 2019-12-09 /pmc/articles/PMC6900860/ /pubmed/31827784 http://dx.doi.org/10.1186/s40035-019-0178-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Van Schependom, Jeroen
Guldolf, Kaat
D’hooghe, Marie Béatrice
Nagels, Guy
D’haeseleer, Miguel
Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in
title Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in
title_full Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in
title_fullStr Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in
title_full_unstemmed Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in
title_short Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in
title_sort detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900860/
https://www.ncbi.nlm.nih.gov/pubmed/31827784
http://dx.doi.org/10.1186/s40035-019-0178-4
work_keys_str_mv AT vanschependomjeroen detectingneurodegenerativepathologyinmultiplesclerosisbeforeirreversiblebraintissuelosssetsin
AT guldolfkaat detectingneurodegenerativepathologyinmultiplesclerosisbeforeirreversiblebraintissuelosssetsin
AT dhooghemariebeatrice detectingneurodegenerativepathologyinmultiplesclerosisbeforeirreversiblebraintissuelosssetsin
AT nagelsguy detectingneurodegenerativepathologyinmultiplesclerosisbeforeirreversiblebraintissuelosssetsin
AT dhaeseleermiguel detectingneurodegenerativepathologyinmultiplesclerosisbeforeirreversiblebraintissuelosssetsin